

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-830-A; RPI 600/005)

In the Application of:

Vargeese et al.

Serial No.: 09/887,182

Filed: June 22, 2001

For: METHOD FOR THE CHEMICAL
SYNTHESIS OF OLIGONUCLEOTIDES



Art Unit: Unassigned

Examiner: Unassigned

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached:
 - a. Information Disclosure Statement including 141 cited references;
 - b. PTO Form 1449; and
 - c. Return Receipt Postcard
2. With respect to additional fees:

 X No additional fee is required.
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 4th day of April, 2002.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: April 4, 2002

By: _____

Stephen H. Docter

Stephen H. Docter
Reg. No. 44,659



UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-830-A; RPI 600/005)

PATENT

In the Application of:)	
)	
Vargeese et al.)	Art Unit: Unassigned
)	
Serial No.: 09/887,182)	
)	Examiner: Unassigned
Filed: June 22, 2001)	
)	
For: METHOD FOR THE CHEMICAL)	
SYNTHESIS OF OLIGONUCLEOTIDES)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231-9999

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

Portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the

references. This Statement is not a representation that the cited references have effective dates early enough to be “prior art” within the meaning of 35 U.S.C. sections 102 or 103.

CITED REFERENCES

U.S. Patent Documents

	Document Number	Filing Date	Name
1.	5,153,319	03/31/86	Caruthers et al
2.	5,132,418	06/18/84	Caruthers et al
3.	4,973,679	09/18/86	Caruthers et al
4.	5,686,599	05/02/95	Tracz
5.	5,804,683	05/05/95	Usman et al
6.	5,831,071	08/29/97	Wincott et al
7.	5,281,701	07/12/91	Winayak
8.	4,923,901	09/04/87	Koester and Coull
9.	5,723,599	03/22/95	Klem and Riley
10.	5,674,856	02/23/95	Kurukawa
11.	5,141,813	08/28/89	Nelson
12.	5,419,966	07/12/93	Reed
13.	4,458,066	03/24/81	Caruthers et al
14.	5,252,723	11/27/90	Bhatt
15.	4,987,071	12/03/86	Cech et al
16.	5,849,902	12/15/98	Arrow et al
17.	5,989,912	12/15/98	Arrow et al
18.	5,834,186	06/02/95	George et al
19.	5,741,679	09/16/94	George et al
20.	5,589,332	05/09/94	Shih et al
21.	5,871,914	06/02/94	Nathan et al
22.	5,334,711	06/22/92	Sproat
23.	5,716,824	04/20/95	Beigelman et al
24.	5,627,053	05/02/95	Usman et al
25.	5,672,695	09/23/91	Eckstein et al
26.	4,306,839	08/23/79	Pien

Foreign Patent Documents

27.	0 325,970	14.01.89	Europe
28.	2,169,605 A	16.12.85	Japan (Yano et al)
29.	94/01446	29.06.93	WO/PCT (Reddy et al)
30.	280,968	10.07.83	Germany (Samuel P. Smith)
31.	97/42202	04.10.96	WO/PCT (Zhang et al.)
32.	92/07065	23.09.91	WO/PCT (Eckstein et al.)
33.	93/15187	28.01.93	WO/PCT (Usman et al.)
34.	97/26270	23.12.96	WO/PCT (Wincott et al.)
35.	00/24931	22.10.99	WO/PCT (Nathan et al.)
36.	00/26226	29.10.99	WO/PCT (Breaker et al.)
37.	98/27104	18.12.97	WO/PCT (Breaker et al.)
38.	99/29842	03.12.98	WO/PCT (Sullenger et al.)
39.	98/13526	26.09.97	WO/PCT (Arrow et al.)
40.	99/54459	19.04.99	WO/PCT (Thompson et al.)
41.	93/23569	29.04.93	WO/PCT (Draper et al.)
42.	93/23057	13.05.93	WO/PCT (Thompson et al.)
43.	94/02595	02.07.93	WO/PCT (Sullivan et al.)
44.	95/04818	04.08.94	WO/PCT (Draper et al.)
45.	95/23225	23.02.95	WO/PCT (Stinchcomb et al.)
46.	95/13380	10.11.94	WO/PCT (Draper et al.)
47.	91/03162	05.06.90	WO/PCT (Ross et al.)
48.	98/28317	19.12.97	WO/PCT (Karpeisky et al.)

Other Documents

49. Usman and Cedergren, *Trends in Biochem, Sci.* 1992, 17, 334-339.
50. Sproat et al., "An Efficient Method for the Isolation and Purification of Oligoribonucleotides," *Nucleosides & Nucleotides* 14:255-273 (1995).
51. Gait et al., "Ch. 2 - Oligoribonucleotide synthesis," in *Oligonucleotides and Analogues: A Practical Approach*, edited by Eckstein, IRL Press, Oxford, pp. 25-48 (1991)
52. Weetall et al., 1974, *Methods in Enzymology*, 34, 59-72.
53. Van Aerschot et al., 1988, *Nucleosides and Nucleotides*, 7, 75-90.
54. Maskos and Southern, 1992, *Nucleic Acids Research*, 20, 1679-1684.
55. Van Ness et al., 1991, *Nucleic Acids Research*, 19, 3345-3350.

56. Katzhendler et al., "The Effect of Spacer, Linkage and Solid Support on the Synthesis of Oligonucleotides," *Tetrahedron* 45:2777-2792 (1989)
57. Hovinen et al., "Novel Solid Supports for the Preparation of 3'-Derivatized Oligonucleotides: Introduction of 3'-Alkylphosphate Tether Groups Bearing Amino, Carboxy, Carboxamido, and Mercapto Functionalities," *Tetrahedron* 50:7203-7218 (1994)
58. Kitamura et al., 2000, *Chem Lett.*, 10, 1134-1135.
59. Katzhendler et al., "Spacer Effect of the Synthesis of Oligodeoxynucleotides by the Phosphite Method," *Reactive Polymers* 6:175-187 (1987)
60. Katzhendler et al, 1989, *Tetrahedron* 45, 2777.
61. Pon et al., "Derivatization of Controlled Pore Glass Beads for Solid Phase Oligonucleotide Synthesis," *BioTechniques* 6:768-775 (1988)
62. Greenberg, ., "Photochemical Release of Protected Oligonucleotides Containing 3'-Glycolate Termini," *Tetrahedron* 51:29-38 (1995)
63. Palom et al., 1991, *Tetrahedron Lett* 34, 2195-2198.
64. Pon & Yu, 1997, *Tetrahedron Lett* 38, 3327-3330.
65. Dell-Aquila et al., 1997, *Tetrahedron Lett.* 38, 5289-5292.
66. Birch-Hirschfeld et al., "A versatile support for the synthesis of oligonucleotides of extended length and scale," *Nucleic Acids Research* 22:1760-1761 (1994).
67. Alul et al., 1991, *Nucleic Acids Research* 19, 1527-1532.
68. Pon, 1993, "Ch. 19 - Solid-Phase Supports for Oligonucleotide Synthesis," in *Methods in Molecular Biology, Volume 20: Protocols for Oligonucleotides and Analogs*, edited by Agrawal, Humana Press, Inc., Totowa, NJ, pp. 465-497 (1993).
69. Pon et al., 1999, *Nucleic Acids Research*, 27, 1531-1538.
70. Limbach et al., "Summary: the modified nucleosides of RNA," *Nucleic Acids Research* 22(12):2183-2196 (1994)
71. Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," *Biochemistry* 35:14090-14097 (1996) (volume no mistakenly listed as 6)
72. Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," *Nucleic Acids Research* 23:2092-2096 (1995)
73. Hammann et al., ., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," *Antisense & Nucleic Acid Drug Development* 9:25-31 (1999)
74. Cech et al., 1988, 260 JAMA 3030.
75. Egholm et al., 1993 *Nature* 365, 566.
76. Stein and Chen, 1993 *Science* 261, 1004.
77. Schmajuk et al., 1999, *J. Biol. Chem.*, 274, 21783-21789,
78. Delihias et al., 1997, *Nature*, 15, 751-753.
79. Stein et al., 1997, *Antisense N. A. Drug Dev.*, 7, 151.
80. Crooke, 2000, *Methods Enzymol.*, 313, 3-45.
81. Crooke, 1998, *Biotech. Genet. Eng. Rev.*, 15, 121-157.
82. Crooke, 1997, *Ad. Pharmacol.*, 40, 1-49.
83. Bass, 2001, *Nature*, 411, 428-429.
84. Elbashir et al., 2001, *Nature*, 411, 494-498.
85. Torrence et al., 1993 *Proc. Natl. Acad. Sci. USA* 90, 1300.
86. Silverman et al., 1999, *Methods Enzymol.*, 313, 522-533.
87. Player and Torrence, 1998, *Pharmacol. Ther.*, 78, 55-113.
88. Duval-Valentin et al., 1992 *Proc. Natl. Acad. Sci. USA* 89, 504.


89. Fox, 2000, *Curr. Med. Chem.*, 7, 17-37.
90. Praseuth et al., 2000, *Biochim. Biophys. Acta*, 1489, 181-206.
91. Sullenger et al., 1990, *Cell*, 63, 601-608.
92. Gold et al., 1995, *Annu. Rev. Biochem.*, 64, 763.
93. Brody and Gold, 2000, *J. Biotechnol.*, 74, 5.
94. Sun, 2000, *Curr. Opin. Mol. Ther.*, 2, 100.
95. Kusser, 2000, *J. Biotechnol.*, 74, 27.
96. Hermann and Patel, 2000, *Science*, 287, 820.
97. Jayasena, 1999, *Clinical Chemistry*, 45, 1628.
98. Scaringe et al., *Nucleic Acids Res.* 1990, 18, 5433-5441.
99. Usman et al., 1987, *J. Am. Chem. Soc.*, 109, 7845.
100. Scaringe et al., 1990, *Nucleic Acids Res.*, 18, 5433.
101. Wincott et al., 1995, *Nucleic Acids Res.* 23, 2677-2684 Wincott et al., 1997, *Methods Mol. Bio.*, 74, 59
102. Christoffersen, *Nature Biotech*, 1997, 2, 483-484.
103. Orgel, 1979, *Proc. R. Soc. London*, B 205, 435.
104. Joyce, 1989, *Gene*, 82, 83-87.
105. Beaudry et al., 1992, *Science* 257, 635-641.
106. Joyce, 1992, *Scientific American* 267, 90-97.
107. Breaker et al., 1994, *TIBTECH* 12, 268.
108. Bartel et al., 1993 *Science* 261:1411-1418.
109. Szostak, 1993, *TIBS* 17, 89-93.
110. Kumar et al., 1995, *FASEB J.*, 9, 1183.
111. Breaker, 1996, *Curr. Op. Biotech.*, 7, 442.
112. Santoro et al., 1997, *Proc. Natl. Acad. Sci.*, 94, 4262.
113. Tang et al., 1997, *RNA* 3, 914.
114. Nakamaye Y Eckstein, 1994, *supra*.
115. Long & Uhlenbeck, 1994, *supra*.
116. Ishizaka et al., 1995, *supra*.
117. Vaish et al., 1997, *Biochemistry* 36, 6495.
118. Zaug et al., 324, *Nature* 429 1986.
119. Uhlenbeck, 1987 *Nature* 328, 596.
120. Kim et al., 84 *Proc. Natl. Acad. Sci. USA* 8788, 1987.
121. Dreyfus, 1988, *Einstein Quart. J. Bio. Med.*, 6, 92.
122. Haseloff and Gerlach, 334 *Nature* 585, 1988.
123. Jefferies et al., 17 *Nucleic Acids Research* 1371, 1989.

124. Usman & McSwiggen, 1995 *Ann. Rep. Med. Chem.* 30, 285-294.
125. Christoffersen and Marr, 1995 *J. Med. Chem.* 38, 2023-2037.
126. Warashina et al., 1999, *Chemistry and Biology*, 6, 237-250.
127. Woo-Pong, Nov. 1994, *BioPharm*, 20-33.
128. Mukhopadhyay & Roth, 1996, *Crit. Rev. in Oncogenesis* 7, 151-190.
129. Mitra et al., 1996, *Proc Nat Acad Sci USA* 93, 6780-6785.
130. Perrault et al., 1990 *Nature* 344, 565.
131. Picken et al., 1991, *Science* 253, 314.
132. Usman and Cedergren, 1992, *Trends in Biochem. Sci.* 17, 334-339.
133. Beigelman et al., 1995, *J. Biol. Chem.*, 270, 25702.
134. Karpeisky et al., 1998, *Tetrahedron Lett.*, 39, 1131.
135. Earnshaw and Gait, 1998, *Biopolymers (Nucleic acid Sciences)*, 48, 39-55.
136. Verma and Eckstein, 1998, *Annu. Rev. Biochem.*, 67, 99-134.
137. Burlina et al., 1997, *Bioorg. Med. Chem.*, 5, 1999-2010.
138. Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," *Methods in Enzymology* 211:3-19 (1992)
139. Beaucage and Iyer, 1993, *Tetrahedron* 49, 1925.
140. Hunziker and Leumann, 1995, *Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods*, VCH, 331-417, and Mesmaeker et al., 1994, *Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research*, ACS, 24-39.
141. Nathans et al., 1975 *Ann. Rev. Biochem.* 44: 273.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Date: April 4, 2002

By: 
Stephen H. Docter
Registration No. 44,659